ImPact Biotech is advancing its clinical pipeline with updates on Padeliporfin vascular-targeted photodynamic therapy (VTP), particularly in the Phase 3 ENLIGHTED trial for low-grade upper tract urothelial carcinoma (UTUC) and a Phase 1 trial for unresectable locally advanced pancreatic ductal adenocarcinoma (LA-PDAC). The company will present updated data at the American Urological Association (AUA) and American Society of Clinical Oncology (ASCO) annual meetings in May and June 2026, respectively, with topline results from the ENLIGHTED trial anticipated later in 2026.

The significance of these trials lies in Padeliporfin VTP’s potential to provide a minimally invasive treatment option for patients with solid tumors. Preliminary data from the Phase 1 LA-PDAC trial indicate a well-tolerated safety profile and promising efficacy signals, suggesting that Padeliporfin VTP could address a substantial unmet medical need in this patient population. The ongoing ENLIGHTED trial also shows potential for Padeliporfin to become a best-in-class therapy for low-grade UTUC, which may facilitate strategic partnerships for commercialization.

The key takeaway from these developments is the potential shift in treatment paradigms for solid tumors, particularly in settings with high unmet needs. The favorable safety and efficacy profile observed thus far may accelerate the registrational pathway for Padeliporfin VTP, potentially leading to earlier market entry and offering new therapeutic options for patients. This progress underscores the importance of innovative approaches in oncology and their implications for drug development timelines in the field.

Source: globenewswire.com